KEEP UP WITH THE LATEST IN INDUSTRY NEWS!
From news about new medicines, pharmacy business insights, and the pharmaceutical industry in general—this is your source!
DrugTopics articles
- FDA Roundup: Agency Highlights from July 2024 July 26, 2024Check out these important FDA updates from the month of July 2024.
- Prenatal Cannabis Use and Maternal Health Outcomes July 26, 2024Researchers aimed to address the associations between prenatal cannabis use and maternal health outcomes over a 9-year period.
- Slideshow: Managing The Peak of Asthma Season July 25, 2024The American College of Allergy, Asthma, and Immunology (ACAAI) recently released its 5 tips to help children and their parents stay educated on asthma peak month.
- Nemolizumab for Atopic Dermatitis Shows Positive Results in Phase 3 Trials July 25, 2024Galderma said the FDA has accepted the company’s Biologics License Application for the therapy based on data from the trials.
- Q&A: The Superman Pharmacist Shares His Vision For Community Pharmacy July 25, 2024In the final part of his conversation on Over the Counter, Mayank Amin, PharmD, RPh, MBA, reflects on 5-years worth of learnings at Skippack Pharmacy and offers candid perspectives on the future of community pharmacy.
- Q&A: Discovering the Powerful Impact of Community Pharmacy July 24, 2024In part 3 of his conversation with Drug Topics on Over the Counter, Mayank Amin, PharmD, RPh, MBA, continues his inspiring story of reopening Skippack Pharmacy and details the beginnings of The Superman Pharmacist.
- Voices in Pharmacy: July 2024 Expert Interviews July 24, 2024Check out these featured Drug Topics interviews from July 2024.
- Lenacapavir for PrEP Shows 100% Efficacy in Preventing HIV July 24, 2024Full efficacy and safety results for the phase 3 PURPOSE 1 trial were announced by Gilead at AIDS 2024.
- Democrats, Republicans Come Together to Condemn PBMs July 24, 2024In a House Committee on Oversight and Accountability hearing, Democrats and Republicans took a bipartisan stance to question the role major PBMs play regarding rising drug costs in the US.
- Dovato Offers Similar Efficacy, Less Weight Gain to Biktarvy in Head-to-Head Trial July 24, 2024PASO DOBLE is the largest head-to-head, phase 4 randomized clinical trial comparing DTG/3TC and BIC/FTC/TAF in patients with HIV.
Pharmacy Times articles
- Blood Test May Predict CAR T-Cell Therapy Outcomes for Patients With Multiple Myeloma July 26, 2024Increased levels of absolute lymphocyte count are associated with improved response to BCMA-targeted CAR T-cell therapy.
- Persistent Epigenetic Changes in Immune Cells Following Hepatitis C Recovery July 26, 2024Study finds traces of “epigenetic scars” on the immune cells of patients who recovered from chronic hepatitis C infection.
- Personalized Simulations Can Predict Outcomes for Treatment in Patients With Diffuse Large B-Cell Lymphoma July 26, 2024The new approach could optimize precision medicine and lead to better outcomes across a variety of disease states.
- Indole-3-Propionic Acid Shows Long-Term Protection Against Asthma July 26, 2024The molecule can be a potential treatment that counters effects of early-life antibiotics, which can impact the gut microbiota and increase the risk of childhood atopy and asthma.
- Drugflation Is Soaring, But It Can Be Tamed July 26, 2024Unbridled drugflation, or a point-in-time measure of the rising cost of pharmacy benefits, is taking its toll on corporate bottom lines and household budgets.
- JNJ-2056, Targeting Tau Protein, Receives FDA Fast Track Designation for Alzheimer Disease July 26, 2024The FDA’s designation builds off positive results in a phase 1b/2a clinical trial, showing that the vaccine can effectively target the Tau protein.
- Giroctocogene Fitelparvovec Reduces Total Annualized Bleeding Rate for Hemophilia A July 26, 2024The investigational drug achieved non-inferiority compared to routine Factor VIII.
- Optimizing Cholesterol Management With Injectable Lipid-Lowering Therapies July 26, 2024Pharmacologic approaches can increase the use of injectables.
- Unique Roles for Pharmacy Technicians Can Enhance Patient Care and Safety July 26, 2024Expanding horizons can take many forms for pharmacy techs
- Manifestation of Pneumococcal Disease in Adults July 26, 2024Medical professionals describe how pneumococcal disease manifests in adults, detailing its potentially lethal consequences such as sepsis or severe pneumonia, and explain how vaccination can effectively mitigate these serious health risks.
Helping You Navigate the Returns Process!
Pedigree Statement
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with it’s clients…
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with its clients. This is to ensure that the reverse distribution portion of the supply chain that we service keeps its functionality and integrity for our customers and the public.
Several pedigree and distribution level issues have been raised in the industry. Discounted, indigent-pricing, short dated, bulk purchase, secondary distribution, or DSCSA non-compliant sales could affect the credit available for a product based on a manufacturers determination. We ask that you do not return these products for credit as they are not eligible in most cases. Flash Returns LLC may choose to dispose of these on the pharmacies behalf at no charge if the cost is low relative to the return. Most customers purchasing products from reputable wholesalers will not encounter these issues, however all pharmacies are asked to acknowledge our policy on pedigree and legitimacy of product here and by signing the PSA before a return is initiated.
Some manufacturers may require proof the price paid for a product and what wholesaler distributed the product. Issues causing triggering this could be: bulk or large quantities of single items or lots, or products purchased speculatively. In some cases we may request invoices from the customer to ensure Flash Returns or manufacturer policy is being met. If none are available or if the information isn’t accepted by the manufacturer it could cause the return to be non-returnable.
Flash Returns, LLC cannot guarantee or be liable for the value or credit for products that were purchased outside of manufacturer accepted distribution channels. This could include products: purchased from a wholesaler that is not an approved vendor, products not purchased directly from a particular manufacturer, purchased on a speculative basis, diverted or counterfeit products, foreign products, and any product purchased on a non-returnable basis, including short-dated product purchased at discounted pricing.
At any time, Flash Returns, LLC or a manufacturer may require invoices or pedigree information demonstrating proof of purchase. If product has been shipped by Flash Returns, LLC or the Customer to a manufacturer or their agent, Flash Returns, LLC cannot guarantee or facilitate the return of product to the Customer. Manufacturers reverse the right to destroy product they deem not credit worthy or suspect. Manufacturers agreeing to return product to customers will do so at the customers expense. Flash Returns, LLC shall not be responsible for reimbursing a Customer for such product.
If Customer is unable to have product returned within 21 days, product is subject to be destroyed without any payment or credit issued to Customer. In any dispute, failure by Customer to provide invoices for a product or pedigree if requested shall release Flash Returns, LLC from any and all liability of products involved in dispute including the full value of the product. More information on drug pedigrees is available on the FDA website at:
Pedigree Statement
P: 833.553.5274
E: SignUp@FlashReturns.com